MedTrace Logo

Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis

NCT00560326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-09-01

No results posted yet for this study

Summary

The objective of this study is to assess the safety and efficacy of 0.03% tacrolimus ointment as long-term treatment in paediatric patients with atopic dermatitis.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Tacrolimus Ointment 0.03%

Once or twice daily topical application

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Europe B.V.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
30 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-12-31

Countries

  • Canada
  • Finland
  • Ireland
  • Latvia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560326 on ClinicalTrials.gov